About Flexion Therapeutics (NASDAQ:FLXN)
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $931.2 million
- Outstanding Shares: 31,905,000
Average Prices:- 50 Day Moving Avg: $25.18
- 200 Day Moving Avg: $22.57
- 52 Week Range: $15.93 - $32.25
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.31
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $6.38 per share
- Price / Book: 3.81
Profitability:- EBITDA: ($87,640,000.00)
- Return on Equity: -53.94%
- Return on Assets: -38.24%
Debt:- Debt-to-Equity Ratio: 0.74%
- Current Ratio: 18.29%
- Quick Ratio: 18.29%
Misc:- Average Volume: 1.01 million shs.
- Beta: 1.12
- Short Ratio: 11.24
Frequently Asked Questions for Flexion Therapeutics (NASDAQ:FLXN)
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics, Inc. (NASDAQ:FLXN) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.11. View Flexion Therapeutics' Earnings History.
Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?
9 brokerages have issued 12-month price targets for Flexion Therapeutics' stock. Their predictions range from $0.02 to $570.00. On average, they expect Flexion Therapeutics' share price to reach $88.50 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.
What are analysts saying about Flexion Therapeutics stock?
Here are some recent quotes from research analysts about Flexion Therapeutics stock:
- 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (10/17/2017)
- 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
- 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Acceleron Pharma (XLRN), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), AnaptysBio (ANAB), Radius Health (RDUS), Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Sangamo Therapeutics (SGMO), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM) and REGENXBIO (RGNX).
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Patrick J. Mahaffy, Chairman of the Board
- Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director
- Neil Bodick M.D., Ph.D., Chief Scientific Officer
- Mark Levine, Vice President, General Counsel
- John Magee, Vice President - Sales
- Mark Fraga, Vice President - Marketing
- Scott Kelley M.D., Vice President - Medical Affairs
- Dan Thornton, Vice President - Market Access
- Yamo Deniz M.D., Chief Medical Officer
- Mark P. Stejbach, Director
How do I buy Flexion Therapeutics stock?
Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of Flexion Therapeutics stock can currently be purchased for approximately $24.28.
MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Flexion Therapeutics (NASDAQ:FLXN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 7 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $88.50 (264.51% upside) |
Consensus Price Target History for Flexion Therapeutics (NASDAQ:FLXN)
Analysts' Ratings History for Flexion Therapeutics (NASDAQ:FLXN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/10/2017 | Laidlaw | Reiterated Rating | Buy | $35.00 -> $38.00 | N/A |  |
| 10/10/2017 | Janney Montgomery Scott | Boost Price Target | Buy -> Fair Value | $570.00 | N/A | |
| 10/9/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $35.00 -> $37.00 | N/A | |
| 10/9/2017 | Needham & Company LLC | Boost Price Target | Buy -> Buy | $36.00 -> $42.00 | N/A | |
| 10/6/2017 | Wells Fargo & Company | Set Price Target | Buy | $32.00 -> $39.00 | N/A | |
| 10/4/2017 | Northland Securities | Reiterated Rating | Buy | $40.00 | Medium | |
| 9/11/2017 | Royal Bank Of Canada | Set Price Target | Buy | $44.00 | Low | |
| 6/12/2017 | Cantor Fitzgerald | Set Price Target | Buy | $40.00 | Low | |
| 12/22/2016 | Raymond James Financial, Inc. | Initiated Coverage | Strong-Buy | $35.00 | N/A | |
| 11/8/2016 | BCS | Lower Price Target | | $0.65 -> $0.02 | N/A | |
| 9/6/2016 | Lake Street Capital | Reiterated Rating | Buy | $38.00 | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Flexion Therapeutics (NASDAQ:FLXN)Earnings History by Quarter for Flexion Therapeutics (NASDAQ FLXN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | ($0.80) | ($0.91) | | | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.73) | ($0.75) | | | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.71) | ($0.79) | | | View | Listen | |
| 11/7/2016 | Q3 | ($0.63) | ($0.65) | | | View | Listen | |
| 8/3/2016 | Q2 | ($0.67) | ($0.63) | | | View | N/A | |
| 5/12/2016 | Q1 | ($0.61) | ($0.78) | | | View | Listen | |
| 3/10/2016 | Q4 2015 | ($0.58) | ($0.63) | | | View | N/A | |
| 11/9/2015 | Q3 | ($0.60) | ($0.52) | | | View | Listen | |
| 8/6/2015 | Q215 | ($0.54) | ($0.58) | | | View | N/A | |
| 5/7/2015 | Q115 | ($0.56) | ($0.43) | | | View | N/A | |
| 3/23/2015 | Q4 2014 | ($0.46) | ($0.47) | | | View | N/A | |
| 11/13/2014 | Q314 | ($0.54) | ($0.45) | | | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.55) | ($0.38) | | | View | N/A | |
| 5/8/2014 | Q1 2014 | ($0.53) | ($0.86) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Flexion Therapeutics (NASDAQ:FLXN)Current Year EPS Consensus Estimate: $-3.85 EPS
Next Year EPS Consensus Estimate: $-3.32 EPS
Dividend History for Flexion Therapeutics (NASDAQ:FLXN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Flexion Therapeutics (NASDAQ:FLXN)Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 83.26%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/5/2017 | Yamo Deniz | Insider | Buy | 1,000 | $24.20 | $24,200.00 | |
| 9/1/2017 | Yamo Deniz | Insider | Buy | 3,000 | $24.15 | $72,450.00 | |
| 8/31/2017 | Yamo Deniz | Insider | Buy | 1,375 | $25.40 | $34,925.00 | |
| 6/16/2017 | Mark Stejbach | Director | Buy | 1,580 | $17.02 | $26,891.60 | |
| 6/5/2017 | Michael D Clayman | Insider | Buy | 5,000 | $17.23 | $86,150.00 | |
| 4/17/2017 | Neil Bodick | Insider | Sell | 5,000 | $28.23 | $141,150.00 | |
| 3/23/2017 | Frederick W Driscoll | CFO | Sell | 3,000 | $23.00 | $69,000.00 | |
| 3/17/2017 | Neil Bodick | Insider | Sell | 5,000 | $20.41 | $102,050.00 | |
| 2/24/2017 | Neil Bodick | Insider | Sell | 5,000 | $19.15 | $95,750.00 | |
| 1/20/2017 | Neil Bodick | Insider | Sell | 5,000 | $18.35 | $91,750.00 | |
| 12/21/2016 | Neil Bodick | Insider | Sell | 10,000 | $18.46 | $184,600.00 | |
| 12/1/2016 | Samuel D Colella | Director | Buy | 10,000 | $16.38 | $163,800.00 | |
| 11/23/2016 | Michael D Clayman | Insider | Buy | 1,667 | $18.41 | $30,689.47 | |
| 11/22/2016 | Michael D Clayman | Insider | Buy | 1,666 | $17.95 | $29,904.70 | |
| 11/21/2016 | Michael D Clayman | Insider | Buy | 1,666 | $17.90 | $29,821.40 | |
| 11/21/2016 | Samuel D Colella | Director | Buy | 33,333 | $18.00 | $599,994.00 | |
| 6/21/2016 | Samuel D Colella | Director | Buy | 25,504 | $13.71 | $349,659.84 | |
| 6/20/2016 | Samuel D Colella | Director | Buy | 6,778 | $13.84 | $93,807.52 | |
| 6/14/2016 | C Ann Merrifield | Director | Buy | 1,000 | $13.39 | $13,390.00 | |
| 6/8/2016 | Samuel D Colella | Director | Buy | 714,285 | $14.00 | $9,999,990.00 | |
| 5/20/2016 | Michael D Clayman | CEO | Buy | 2,000 | $10.41 | $20,820.00 | |
| 5/19/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.65 | $19,300.00 | |
| 5/19/2016 | Neil Bodick | Insider | Buy | 850 | $10.00 | $8,500.00 | |
| 5/18/2016 | Michael D Clayman | CEO | Buy | 2,000 | $10.23 | $20,460.00 | |
| 5/18/2016 | Neil Bodick | Insider | Buy | 2,100 | $10.20 | $21,420.00 | |
| 5/17/2016 | Frederick W Driscoll | CFO | Buy | 2,500 | $9.87 | $24,675.00 | |
| 5/17/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.73 | $19,460.00 | |
| 5/17/2016 | Neil Bodick | Insider | Buy | 800 | $9.60 | $7,680.00 | |
| 5/16/2016 | Frederick W Driscoll | CFO | Buy | 2,500 | $9.19 | $22,975.00 | |
| 5/16/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.51 | $19,020.00 | |
| 5/16/2016 | Neil Bodick | Insider | Buy | 1,250 | $9.22 | $11,525.00 | |
| 9/11/2015 | C Ann Merrifield | Director | Buy | 1,000 | $23.00 | $23,000.00 | |
| 6/22/2015 | A/S Novo | Major Shareholder | Sell | 150,000 | $20.61 | $3,091,500.00 | |
| 3/16/2015 | Neil Bodick | Insider | Sell | 4,000 | $25.28 | $101,120.00 | |
| 3/10/2015 | Neil Bodick | Insider | Sell | 4,000 | $24.26 | $97,040.00 | |
| 3/4/2015 | Neil Bodick | Insider | Sell | 4,000 | $23.45 | $93,800.00 | |
| 2/26/2015 | Neil Bodick | Insider | Sell | 4,000 | $22.44 | $89,760.00 | |
| 12/17/2014 | A/S Novo | Major Shareholder | Buy | 500,000 | $17.00 | $8,500,000.00 | |
| 2/18/2014 | A/S Novo | Insider | Buy | 692,308 | $13.00 | $9,000,004.00 | |
| 2/18/2014 | Bradley J Phd Bolzon | Director | Buy | 307,692 | $13.00 | $3,999,996.00 | |
| 2/18/2014 | Sofinnova Partners Sas | Major Shareholder | Buy | 230,769 | $13.00 | $2,999,997.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Flexion Therapeutics (NASDAQ:FLXN)
Latest Headlines for Flexion Therapeutics (NASDAQ:FLXN)
| Source: |
|
| Date | Headline |
|---|
 | Flexion Therapeutics, Inc. (FLXN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - October 17 at 10:58 PM |
 | Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers
finance.yahoo.com - October 17 at 7:25 PM |
 | Jim Cramer Advises His Viewers On Flexion Therapeutics, Blackhawk Network And Carrizo Oil & Gas - Benzinga
www.benzinga.com - October 13 at 9:22 PM |
 | ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus - Nasdaq
www.nasdaq.com - October 12 at 1:19 AM |
 | Flexion's Latest FDA Approval Reignites Takeover Chatter - TheStreet.com
www.thestreet.com - October 12 at 1:19 AM |
 | Flexion Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - October 12 at 1:19 AM |
| Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers
finance.yahoo.com - October 11 at 8:16 PM |
| Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 11 at 8:16 PM |
 | Flexion Therapeutics Inc. (FLXN) Is Falling On Offering News
www.rttnews.com - October 10 at 9:28 PM |
| Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating
finance.yahoo.com - October 10 at 9:28 PM |
| Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
finance.yahoo.com - October 10 at 9:28 PM |
| Flexion CEO on non-opioid knee pain treatment
finance.yahoo.com - October 10 at 9:28 PM |
| Flexion's Latest FDA Approval Reignites Takeover Chatter
finance.yahoo.com - October 10 at 4:27 PM |
| Flexion Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 10 at 4:27 PM |
| Flexion Therapeutics, Inc. (FLXN) Given "Buy" Rating at Laidlaw
www.americanbankingnews.com - October 10 at 3:50 PM |
| Flexion Therapeutics, Inc. (FLXN) PT Raised to $570.00
www.americanbankingnews.com - October 10 at 9:14 AM |
 | Flexion Therapeutics (FLXN) PT Raised to $42 at Needham & Company on 'FDA Approval for Zilretta with ... - StreetInsider.com
www.streetinsider.com - October 9 at 6:57 PM |
| Flexion Therapeutics Just Hit A Major Milestone - Benzinga
www.benzinga.com - October 9 at 6:57 PM |
| BMO Capital Markets Increases Flexion Therapeutics, Inc. (FLXN) Price Target to $37.00
www.americanbankingnews.com - October 9 at 4:32 PM |
| Flexion Therapeutics, Inc. (FLXN) Price Target Raised to $42.00
www.americanbankingnews.com - October 9 at 8:54 AM |
| FDA OKs Flexion's Zilretta For Osteoarthritis Knee Pain
www.nasdaq.com - October 8 at 5:30 PM |
| Flexion Therapeutics (FLXN) Receives FDA Approval of Zilretta for Osteoarthritis (OA) Knee Pain
www.streetinsider.com - October 7 at 9:14 PM |
| Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release
www.nasdaq.com - October 7 at 12:08 AM |
| Flexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & Company
www.americanbankingnews.com - October 6 at 7:18 PM |
 | Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection - MarketWatch
www.marketwatch.com - October 6 at 7:08 PM |
 | FDA OKs Flexion's Zilretta for osteoarthritis knee pain - Seeking Alpha
seekingalpha.com - October 6 at 7:08 PM |
| Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion's knee pain drug gets FDA nod
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection
finance.yahoo.com - October 6 at 7:07 PM |
| Burlington biotech Flexion eyes expansion after FDA approves pain drug
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion shares surge on FDA approval for its non-opioid knee pain medication
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion soars on FDA drug approval
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion Secures FDA Nod for Osteoarthritis Knee Pain Treatment, Shares Skyrocket
finance.yahoo.com - October 6 at 7:07 PM |
| Edited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - October 6 at 7:07 PM |
| This Biotech Could Reap North Of $1 Billion For Painkiller
finance.yahoo.com - October 6 at 7:07 PM |
| Flexion's knee pain drug gets FDA nod, shares hit life high
finance.yahoo.com - October 6 at 7:07 PM |
| Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating
finance.yahoo.com - October 5 at 10:55 PM |
 | Big Day on Deck for Flexion Therapeutics - Motley Fool
www.fool.com - October 5 at 5:55 PM |
| What You Must Know About Flexion Therapeutics Inc’s (FLXN) Risks
finance.yahoo.com - October 5 at 8:55 AM |
| Flexion Therapeutics, Inc. (FLXN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 4 at 6:02 PM |
| Outlook for FDA Approval of Zilretta
finance.yahoo.com - October 4 at 5:39 PM |
| Notable Monday Option Activity: FLXN, VSM, PKE
www.thestreet.com - October 2 at 2:29 PM |
| 3 Biotech and Pharma Stocks with Key FDA Catalysts this October
finance.yahoo.com - October 2 at 2:29 PM |
| Interesting FLXN Put And Call Options For May 2018
www.thestreet.com - September 28 at 6:08 PM |
| Contrasting AveXis (AVXS) & Flexion Therapeutics (FLXN)
www.americanbankingnews.com - September 24 at 6:18 PM |
| Implied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options - Nasdaq
www.nasdaq.com - September 19 at 11:46 PM |
| Implied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options
finance.yahoo.com - September 19 at 6:43 PM |
| Flexion Therapeutics, Inc. (FLXN) Given "Buy" Rating at Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM |
| Insider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,375 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM |
| Insider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,000 Shares of Stock
www.americanbankingnews.com - September 15 at 8:30 PM |
Flexion Therapeutics (FLXN) Chart for Thursday, October, 19, 2017
